+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

U.S. Topical Pain Relief Market by Therapeutic Class and Distribution Channel: Opportunity Analysis and Industry Forecast, 2018-2025

  • ID: 4828617
  • Report
  • Region: United States
  • 128 pages
  • Allied Analytics LLP
1 of 3
The U.S. topical pain relief market size was valued at $2,324 million in 2017, and is projected to reach $3,730 million by 2025 at a CAGR of 6.0% from 2018 to 2025.

Pain is a distressing feeling, which is usually caused by intense or damaging stimuli. Pain is most prevalent symptom associated with most of chronic conditions. Pain management involves the employment of medications or analgesics and therapies to treat several pain conditions. Whenever, these medications are applied directly to the skin they are known as topical pain relief. These analgesics include non-steroidal anti-inflammatory drugs, anesthetics, capsaicin, and opioids. These medications are present as creams, ointments, gels, and transdermal patches. They are mostly available as over-the-counter (OTC) products while some are available through prescription only.

Market dynamics

The growth of the U.S. topical pain relief market is majorly driven by increase in prevalence of arthritis and other bone-related conditions, diabetic neuropathy, leading to pain. Other factors that boost the market growth include rise in adoption of topical pain relief products as they cause lesser side effects as compared to oral pain relief, upsurge in geriatric population across the U.S., and increase in demand for topical pain relief by sports players. However, factors such as topical pain relief medications can cause irritated skin and they have a strong odor or unpleasant smell that hamper the market growth. Conversely, the development of online platform for the topical therapeutics is expected to provide lucrative growth opportunities for the market.

Market segmentation

The U.S. topical pain relief market is segmented based on therapeutic class, type, formulation, and distribution channel. On the basis of therapeutic class, the market is segmented into non-opioids and opioids. The non-opioids segment is further divided into nonsteroidal anti-inflammatory drugs (NSAIDS), methyl salicylate, capsaicin, lidocaine, and other non-opioids. The opioids segment is further bifurcated into buprenorphine and fentanyl. Non-opioids segment accounted for the largest U.S. topical pain relief market share in 2017, and is expected to continue this trend throughout the forecast period owing to high preferability and easy availability of non-opioids drugs.

By type, the U.S. topical pain relief market is segmented into prescription pain relief and over-the-counter (OTC) relief. Over-the-counter pain relief segment accounted for the largest market share in 2017 due to easy availability and high demand for topical pain relief products by sportsperson. Based on formulation, the market is classified into cream, gel, spray, patch, and others. Cream-based pain relief segment accounted for the largest market share in 2017 owing to high availability of these products with high success rate and lesser side effects. On the other hand, patch pain relief segment is expected to grow at a CAGR of 7.6% during the forecast period.

The distribution channels covered in the study include pharmacies & drug stores, e-commerce, and retail & grocery stores. Pharmacies & drug stores are the major revenue contributors in the U.S. topical pain relief market due to higher presence and wide availability of drugs. On the other side, e-commerce segment is anticipated to exhibit fastest U.S. topical pain relief market growth during the forecast period owing to higher digital literacy among the population. Moreover, these pharmacies offer various advantages such as fewer expenses, more convenience, price comparisons, and easy access to patient reviews, which drive the market growth of this segment.

The key players of this market include Johnson & Johnson, Novartis AG, GlaxoSmithKline Plc., Pfizer Inc., Reckitt Benckiser Group Plc., Sanofi S.A., Topical BioMedics, Inc., AdvaCare Pharma, Sun Pharmaceutical Industries Ltd., and Nestle S.A.

Other players (these players are not profiled in the report and the same can be included on request) in the value chain include Troy Healthcare, LLC, Emami Group, Chattem, Inc., Exzell Pharma, and Performance Health Technologies, Inc.

Key Benefits for US topical pain relief market:
The study provides an in-depth analysis of the current U.S. topical pain relief market trends and future estimations from 2017 to 2025 to elucidate the imminent investment pockets.
Comprehensive analysis of factors that drive and restrict the U.S. topical pain relief market growth is provided.
Identification of factors instrumental in changing the market scenario, rise in opportunities, and identification of key companies that can influence this market on a U.S. scale are provided.

Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the market.
US topical pain relief Key market segments:

By Therapeutic Class
Non-opioids
Non-steroidal Anti-Inflammatory Drugs (NSAIDS)
Methyl Salicylate
Capsaicin
Lidocaine
Other Non-opioids
Opioids
Buprenorphine
Fentanyl

By Type
Prescription Pain Relief
Over-the-counter (OTC) Pain Relief

By Formulation
Cream
Gel
Spray
Patch
Others

By Distribution Channel
Pharmacies & Drug Stores
E-commerce
Retail & Grocery Stores
Note: Product cover images may vary from those shown
2 of 3
CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key benefits for stakeholders
1.3. Key market segments

1.3.1. List of key players profiled in the report

1.4. Research methodology

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. Key findings of the study
2.2. CXO perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings

3.2.1. Top investment pockets

3.3. Top player positioning, 2017
3.4. Market dynamics

3.4.1. Drivers

3.4.1.1. Increase in prevalence of arthritis
3.4.1.2. Growth in geriatric population
3.4.1.3. High demand for topical pain relief products by sportsperson
3.4.1.4. Lesser side effects caused by topical pain relief products as compared to oral medicines

3.4.2. Restraints

3.4.2.1. Topical pain relief sometimes cause skin irritants
3.4.2.2. Topical pain relief is characterized by unpleasant odor

3.4.3. Opportunities

3.4.3.1. Emergence of online pharmacy

3.4.4. Impact analysis

3.5. U.S. patent analysis by year (2014-2019)

CHAPTER 4: U.S. TOPICAL PAIN RELIEF MARKET, BY THERAPEUTIC CLASS

4.1. Overview

4.1.1. Market size and forecast

4.2. Non-opioids

4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by type

4.2.2.1. Nonsteroidal anti-inflammatory drugs (NSAIDS)

4.2.2.1.1. Market size and forecast

4.2.2.2. Methyl salicylates

4.2.2.2.1. Market size and forecast

4.2.2.3. Capsaicin

4.2.2.3.1. Market size and forecast

4.2.2.4. Lidocaine

4.2.2.4.1. Market size and forecast

4.2.2.5. Other non-opioids

4.2.2.5.1. Market size and forecast

4.3. Opioids

4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by type

4.3.2.1. Buprenorphine

4.3.2.1.1. Market size and forecast

4.3.2.2. Fentanyl

4.3.2.2.1. Market size and forecast

CHAPTER 5: U.S. TOPICAL PAIN RELIEF MARKET, BY FORMULATION

5.1. Overview

5.1.1. Market size and forecast

5.2. Cream

5.2.1. Market size and forecast

5.3. Gel

5.3.1. Market size and forecast

5.4. Spray

5.4.1. Market size and forecast

5.5. Patch

5.5.1. Market size and forecast

5.6. Others

5.6.1. Market size and forecast

CHAPTER 6: U.S. TOPICAL PAIN RELIEF MARKET, BY TYPE

6.1. Overview

6.1.1. Market size and forecast

6.2. Prescription pain relief

6.2.1. Market size and forecast

6.3. Over-the-counter pain relief

6.3.1. Market size and forecast

CHAPTER 7: U.S. TOPICAL PAIN RELIEF MARKET, BY DISTRIBUTION CHANNEL

7.1. Overview

7.1.1. Market size and forecast

7.2. Pharmacies & drug stores

7.2.1. Market size and forecast

7.3. e-Commerce

7.3.1. Market size and forecast

7.4. Retail & grocery stores

7.4.1. Market size and forecast

CHAPTER 8: COMPANY PROFILES

8.1. AdvaCare Pharma

8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product Portfolio

8.2. GlaxoSmithKline plc.

8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product Portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments

8.3. Johnson & Johnson

8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product Portfolio
8.3.5. Business performance

8.4. Nestlé S.A.

8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product Portfolio
8.4.5. Business performance

8.5. Novartis AG

8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product Portfolio
8.5.5. Business performance

8.6. Pfizer Inc.

8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product Portfolio
8.6.5. Business performance

8.7. Reckitt Benckiser Group plc

8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product Portfolio
8.7.5. Business performance

8.8. Sanofi

8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product Portfolio
8.8.5. Business performance
8.8.6. Key strategic moves and developments

8.9. Sun Pharmaceutical Industries Ltd.

8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.9.5. Business performance
8.9.6. Key strategic moves and developments

8.10. Topical BioMedics, Inc.

8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product Portfolio
8.10.5. Key strategic moves and developments

*Full List of Tables and Figures Available on Enquiry.

Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Adroll
adroll